Antisense Oligonucleotides for the Study and Treatment of ALS

Area of Science:

• Neurodegenerative diseases
• Molecular medicine
• Genetics

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease marked by motor neuron loss.
• Numerous gene mutations are linked to ALS, often involving toxic gain-of-function mechanisms.
• Antisense oligonucleotides (ASOs) are DNA sequences designed to reduce target gene expression post-transcriptionally.

Purpose of the Study:

• To review the current status of antisense oligonucleotide (ASO) therapies for Amyotrophic Lateral Sclerosis (ALS).
• To outline the successes of ASO therapies from preclinical research to early-stage clinical trials.

Main Methods:

• Review of preclinical and clinical data for ASO therapies targeting ALS-associated genes.
• Discussion of advancements in ASO medicinal chemistry for improved central nervous system delivery.
• Focus on ASOs targeting SOD1, C9orf72, FUS, and ATXN2 genes.

Main Results:

• ASO technology has advanced, enabling safe and effective delivery to the central nervous system.
• ASO therapies targeting key ALS genes (SOD1, C9orf72, FUS, ATXN2) have progressed into clinical trials.
• These therapies show potential for neutralizing toxic gene products implicated in ALS pathogenesis.

Conclusions:

• ASO therapies represent a rapidly developing and promising treatment strategy for both familial and sporadic ALS.
• The review highlights the significant progress made in translating ASO research into clinical applications for ALS patients.